These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 4602057)

  • 1. Clinical pharmacology of isophosphamide.
    Creaven PJ; Allen LM; Alford DA; Cohen MH
    Clin Pharmacol Ther; 1974 Jul; 16(1):77-86. PubMed ID: 4602057
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical trial of isophosphamide (NSC-109724)--results and side effects.
    Bremner DN; McCormick JS; Thomson JW
    Cancer Chemother Rep; 1974; 58(6):889-93. PubMed ID: 4614898
    [No Abstract]   [Full Text] [Related]  

  • 3. Renal dysfunction after treatment with isophosphamide (NSC-109724).
    DeFronzo RA; Abeloff M; Braine H; Humphrey RL; Davis PJ
    Cancer Chemother Rep; 1974; 58(3):375-82. PubMed ID: 4842666
    [No Abstract]   [Full Text] [Related]  

  • 4. Phase II clinical trial of isophosphamide (NSC-109724) in patients with advances breast cancer.
    Ahmann DL; Bisel HF; Hahn RG
    Cancer Chemother Rep; 1974; 58(6):861-5. PubMed ID: 4615785
    [No Abstract]   [Full Text] [Related]  

  • 5. Synthesis and metabolic behavior of the suggested active species of isophosphamide having cytostatic activity.
    Takamizawa A; Matsumoto S; Iwata T; Tochino Y; Katagiri K
    J Med Chem; 1974 Nov; 17(11):1237-9. PubMed ID: 4416021
    [No Abstract]   [Full Text] [Related]  

  • 6. A phase 2 study of intermittent high dose isophosphamide therapy of advanced colorectal cancer.
    Kovach JS; Schutt AJ; Hahn RG; Reitemeier RJ; Moertel CG
    Oncology; 1974; 29(1):34-9. PubMed ID: 4837137
    [No Abstract]   [Full Text] [Related]  

  • 7. Activation of the antineoplastic drug isophosphamide by rat liver microsomes.
    Allen LM; Creaven PJ
    J Pharm Pharmacol; 1972 Jul; 24(7):585-6. PubMed ID: 4403857
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical evaluation of ifosfamide in the treatment of malignant neoplasms].
    Czownicki Z; Utracka B; Till A; Styrna M
    Nowotwory; 1973; 23(3):285-90. PubMed ID: 4757587
    [No Abstract]   [Full Text] [Related]  

  • 9. Isophosphamide as a new acrolein-producing antineoplastic isomer of cyclophosphamide.
    Alarcon RA; Meienhofer J; Atherton E
    Cancer Res; 1972 Nov; 32(11):2519-23. PubMed ID: 5082597
    [No Abstract]   [Full Text] [Related]  

  • 10. [Experiences with single high dosage iphosphamide therapy in metastasizing malignant neoplasms].
    Drings P; Fritsch H
    Verh Dtsch Ges Inn Med; 1972; 78():166-9. PubMed ID: 4353153
    [No Abstract]   [Full Text] [Related]  

  • 11. Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide.
    Connors TA; Cox PJ; Farmer PB; Foster AB; Jarman M
    Biochem Pharmacol; 1974 Jan; 23(1):115-29. PubMed ID: 4811053
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiac and pulmonary effects of high doses of cyclophosphamide and isophosphamide.
    O'Connell TX; Berenbaum MC
    Cancer Res; 1974 Jul; 34(7):1586-91. PubMed ID: 4833912
    [No Abstract]   [Full Text] [Related]  

  • 13. Protection with N-acetyl-L-cysteine (NSC-111180) against isophosphamide (NSC-109724) toxicity and enhancement of therapeutic effect in early murine L1210 leukemia.
    Kline I; Gang M; Woodman RJ; Cysyk RL; Venditti JM
    Cancer Chemother Rep; 1973; 57(3):299-304. PubMed ID: 4751256
    [No Abstract]   [Full Text] [Related]  

  • 14. Metabolism of iphosphamide (2-(2-chloroethylamino)-3-(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide) and production of a toxic iphosphamide metabolite.
    Hill DL; Laster WR; Kirk MC; el-Dareer S; Struck RF
    Cancer Res; 1973 May; 33(5):1016-22. PubMed ID: 4703116
    [No Abstract]   [Full Text] [Related]  

  • 15. [Comparative study of cyclophosphamide, ifosfamide and trofosfamide on Walker-256 carcinosarcoma in embryonated chicken eggs].
    Norpoth K; Witting U; Rauen HM
    Arzneimittelforschung; 1974 Jan; 24(1):86-9. PubMed ID: 4406116
    [No Abstract]   [Full Text] [Related]  

  • 16. In vitro activation of isophosphamide (NSC-109724), a new oxazaphosphorine, by rat liver microsomes.
    Allen LM; Creaven PJ
    Cancer Chemother Rep; 1972 Oct; 56(5):603-10. PubMed ID: 4405717
    [No Abstract]   [Full Text] [Related]  

  • 17. New drugs on the horizon in bronchogenic carcinoma.
    Carter SK
    Cancer; 1972 Nov; 30(5):1402-9. PubMed ID: 4117256
    [No Abstract]   [Full Text] [Related]  

  • 18. Teratogenicity and neonatal toxicity of ifosfamide in mice.
    Bus JS; Gibson JE; Reinke DA
    Proc Soc Exp Biol Med; 1973 Sep; 143(4):965-70. PubMed ID: 4743716
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical conference: facial paralysis. Grand rounds. Massachusetts Eye and Ear Infirmary.
    Schuknecht H; Goodman ML; Weber A; Pappanikou A; Tolpin D
    Ann Otol Rhinol Laryngol; 1974; 83(2):257-63. PubMed ID: 4817439
    [No Abstract]   [Full Text] [Related]  

  • 20. Bronchogenic carcinoma: new drugs available for study.
    Slavik M; Carter SK
    Cancer Chemother Rep 3; 1973 Mar; 4(2):265-9. PubMed ID: 4125744
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.